Bank of America’s Anebulo Pharmaceuticals ANEB Stock Holding History

Bank of America’s Portfolio ANEB Stock Details ANEB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-382	Closed	-$386	–	5746
2025 Q4	$386	Sell	382 -509	-57%	-$1.16K	﹤0.01%	6598
2025 Q3	$2.23K	Sell	891 -2,594	-74%	-$6.1K	﹤0.01%	7390
2025 Q2	$5.02K	Buy	3,485 +37	+1%	+$42	﹤0.01%	7294
2025 Q1	$4.48K	Buy	3,448 +3,372	+4,437%	+$4.96K	﹤0.01%	7238
2024 Q4	$128	Hold	76	–	–	﹤0.01%	7684
2024 Q3	$147	Buy	76 +11	+17%	+$23	﹤0.01%	7635
2024 Q2	$177	Buy	+65	New	+$165	﹤0.01%	7579
2024 Q1	–	Sell	-4	Closed	-$10	–	7707
2023 Q4	$10	Buy	+4	New	+$9	﹤0.01%	7767

Bank of America's ANEB Position: Q1 2026 in Review

Bank of America sold out of Anebulo Pharmaceuticals (ANEB) in Q1 2026, closing a stake of 382 shares — an estimated $386 sold.

Bank of America first reported a position in ANEB in Q4 2023 and held it in 8 quarters. The position peaked at $5.02K in Q2 2025. 0 funds tracked by Wall St. Rank hold ANEB as of Q1 2026.

Bank of America reported no remaining Anebulo Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Bank of America sold 382 Anebulo Pharmaceuticals shares in Q1 2026, an estimated $386.
Bank of America first reported a position in Anebulo Pharmaceuticals in Q4 2023 and held it in 8 quarters.
Bank of America's Anebulo Pharmaceuticals position peaked at $5.02K in Q2 2025.
0 funds tracked by Wall St. Rank held Anebulo Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.